Literature DB >> 6978384

HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes.

M Madigand, J J Oger, R Fauchet, O Sabouraud, B Genetet.   

Abstract

261 multiple sclerosis (MS) patients were HLA-A and -B typed and 94 were HLA-D typed. The results were compared to those of controls typed for HLA-A; HLA-B (356) and HLA-D (113). We confirm and extend earlier findings (Oger et al. 1980b) that some phenotypes could modulate the expression of the MS susceptibility gene linked to B7-DR2: DR3 was found together with DR2 in 12/94 MS and only 3/113 controls and could be marker for an "augmentor" gene. In contrast, B35 and DR1 as well as B12 and DR7 could be markers of protector genes. We compared typing results of patients subgrouped on clinical features. 61 patients with progressive evolution showed increased A1, A1-B8, B8-DR3 and A1-B8-DR3 when compared to 200 patients with remitting evolution. When compared to controls both groups showed increased B7 but only the remitting group showed increased DR2. 71 patients with "benign MS" showed increased B7-DR2 and A3-B7-DR2. 54 patients with "severe disease" showed increased DR3 and A1-B8-DR3 when compared to controls. Both groups showed increased B7 (49.2% and 44.4% versus 25.5% for controls). 120 patients treated greater than 5 years with azathioprine were divided into "no progression" and "progression" while treated. Both groups showed increased B7 when compared to controls. DR2 was increased only in the "no progression" group. B8-DR3 and A1-B8-DR3 were found increased in the "progression" group only. We conclude that two forms of MS exist with different HLA profiles.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978384     DOI: 10.1016/0022-510x(82)90248-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  17 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

2.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus.

Authors:  G C DeLuca; S V Ramagopalan; B M Herrera; D A Dyment; M R Lincoln; A Montpetit; M Pugliatti; M C N Barnardo; N J Risch; A D Sadovnick; M Chao; S Sotgiu; T J Hudson; G C Ebers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-17       Impact factor: 11.205

3.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.

Authors:  O Olerup; J Hillert; S Fredrikson; T Olsson; S Kam-Hansen; E Möller; B Carlsson; J Wallin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  The fine specificity of human T cell lines towards myelin basic protein peptides in southern Italian multiple sclerosis patients.

Authors:  D Montanaro; V Sanna; G Matarese; B B Larby; L Racioppi; P B Carrieri; R Bruno; N J Davey; S Zappacosta; S Fontana
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

5.  HLA complement gene polymorphisms in multiple sclerosis. A study on 80 Italian patients.

Authors:  D Franciotta; E Dondi; R Bergamaschi; G Piccolo; G V d'Eril; V Cosi; M Cuccia
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

6.  HLA and prognosis in multiple sclerosis.

Authors:  B Runmarker; T Martinsson; J Wahlström; O Andersen
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

7.  HLA antigens in Italian multiple sclerosis patients.

Authors:  L La Mantia; M T Illeni; C Milanese; A Salmaggi; M Eoli; G Pellegris; A Nespolo
Journal:  Ital J Neurol Sci       Date:  1991-02

8.  An immunogenetic heterogeneity in multiple sclerosis.

Authors:  J Hillert; M Grönning; H Nyland; H Link; O Olerup
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  HLA antigens-linked genetic control in multiple sclerosis patients resistant and susceptible to infection.

Authors:  G Lamoureux; P Duquette; Y Lapierre; B Cosgrove; G Bourret; L Labrie
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

10.  HLA antigens and progression of multiple sclerosis. Part II.

Authors:  L Dejaegher; M de Bruyere; P Ketelaer; H Carton
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.